» Articles » PMID: 37033996

Patients' IgLON5 Autoantibodies Interfere with IgLON5-protein Interactions

Overview
Journal Front Immunol
Date 2023 Apr 10
PMID 37033996
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Anti-IgLON5 disease is a rare neurological disorder characterized by autoantibodies against IgLON5, and pathological evidence of neurodegeneration. IgLON5 is a cell adhesion molecule but its physiological function is unknown. Our aim was to investigate the IgLON5 interactome and to determine if IgLON5 antibodies (IgLON5-abs) affect these protein interactions.

Methods: IgLON5 interactome was investigated by mass spectrometry sequencing of proteins immunoprecipitated by IgLON5 autoantibodies using cultures of rat cerebellar granular neurons (CGNs). Shedding of IgLON5 was explored using HEK cells transfected with human IgLON5 plasmid and in CGNs. Interactions of IgLON5 with identified binding partners and IgLON5-abs effects were confirmed by immunofluorescence in transfected HEK cells and rat hippocampal neurons.

Results: Patients' IgLON5 antibodies co-precipitated all members of the IgLON family and three 3 additional surface proteins. IgLON5 predominantly establishes homomeric and heteromeric (within the cell) and (between cells)-interactions with other IgLON family members and undergoes spontaneous ectodomain shedding. Antibodies from patients with anti-IgLON5 disease prevent trans-interactions in hippocampal neurons independently of the IgLON5 IgG subclass distribution.

Conclusions: We show a potentially novel pathogenic mechanism of IgLON5-abs that consists in blocking IgLON5 interactions with its binding partners. These findings extend our knowledge about the physiological role of IgLON5 and pave the way to future understanding of the pathological mechanisms of anti-IgLON5 disease.

Citing Articles

Anti-IgLON5 Disease 10 Years Later: What We Know and What We Do Not Know.

Graus F, Sabater L, Gaig C, Gelpi E, Iranzo A, Dalmau J Neurol Neuroimmunol Neuroinflamm. 2024; 12(1):e200353.

PMID: 39705634 PMC: 11666276. DOI: 10.1212/NXI.0000000000200353.


Neuropathological spectrum of anti-IgLON5 disease and stages of brainstem tau pathology: updated neuropathological research criteria of the disease-related tauopathy.

Gelpi E, Reinecke R, Gaig C, Iranzo A, Sabater L, Molina-Porcel L Acta Neuropathol. 2024; 148(1):53.

PMID: 39400557 PMC: 11473580. DOI: 10.1007/s00401-024-02805-y.


IgLON5-IgG: Innocent Bystander or Perpetrator?.

Andersen J, Jeffrey B, Varikatt W, Rodriguez M, Lin M, Brown D Int J Mol Sci. 2024; 25(14).

PMID: 39063198 PMC: 11276813. DOI: 10.3390/ijms25147956.


Antibodies Against ZSCAN1 in Pediatric and Adult Patients With Non-Paraneoplastic ROHHAD Syndrome.

Serafim A, Olive-Cirera G, Ortega-Gonzalez A, Kruer M, Weese-Mayer D, Rand C Neurol Neuroimmunol Neuroinflamm. 2024; 11(5):e200276.

PMID: 38917381 PMC: 11204383. DOI: 10.1212/NXI.0000000000200276.


HLA dependency and possible clinical relevance of intrathecally synthesized anti-IgLON5 IgG4 in anti-IgLON5 disease.

Koneczny I, Macher S, Hutterer M, Seifert-Held T, Berger-Sieczkowski E, Blaabjerg M Front Immunol. 2024; 15:1376456.

PMID: 38827736 PMC: 11141242. DOI: 10.3389/fimmu.2024.1376456.


References
1.
Gruter T, Mollers F, Tietz A, Dargvainiene J, Melzer N, Heidbreder A . Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease. Brain. 2022; 146(2):600-611. DOI: 10.1093/brain/awac090. View

2.
Landa J, Gaig C, Plaguma J, Saiz A, Antonell A, Sanchez-Valle R . Effects of IgLON5 Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration. Ann Neurol. 2020; 88(5):1023-1027. DOI: 10.1002/ana.25857. View

3.
Sanz R, Ferraro G, Fournier A . IgLON cell adhesion molecules are shed from the cell surface of cortical neurons to promote neuronal growth. J Biol Chem. 2014; 290(7):4330-42. PMC: 4326840. DOI: 10.1074/jbc.M114.628438. View

4.
Petit-Pedrol M, Sell J, Planaguma J, Mannara F, Radosevic M, Haselmann H . LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity and memory. Brain. 2018; 141(11):3144-3159. PMC: 6202570. DOI: 10.1093/brain/awy253. View

5.
Patterson K, Dalmau J, Lancaster E . Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia. Ann Neurol. 2017; 83(1):40-51. PMC: 5876120. DOI: 10.1002/ana.25120. View